论文部分内容阅读
慢粒从应用马利兰以后,未再有显著进展,平均生存期依然为3～3.5年。作者从日本200张以上病床的医院,收集慢粒存活7年以上,即上述平均生存期3.5年2倍的病例,视为长期存活者计70例。其中10年以上32例。最长1例22年3个月。现尚存活7年以上29例,10年以上14例。为探讨长期存活因素,作者分析了患者年龄、性别,初诊时红细胞、白细胞、血小板数以及脾肿大情况,未见规律性。23例查了染色体,Ph~1(+)细胞占94～100%。治疗则单用马利兰为多,马利兰及6-MP交替使用者次之。引人注意的是存活10年以上者,其中11例(34%),有5年以上乃至11年未接受任何治疗。70
CML from the application of Maryland after no significant progress, the average survival is still 3 to 3.5 years. The authors collected more than 7 years of chronic pellets from hospitals in Japan with more than 200 beds, that is, 70% of those with a mean survival time of 3.5 years and 2 times. Of which more than 10 years in 32 cases. The longest case of 22 years and 3 months. Now survived more than 7 years in 29 cases, more than 10 years in 14 cases. In order to explore the long-term survival factors, the authors analyzed the patient’s age, gender, initial diagnosis of red blood cells, white blood cells, platelet count and splenomegaly, no regularity. 23 cases checked the chromosome, Ph ~ 1 (+) cells accounted for 94 to 100%. Treatment alone is more than Maryland, Malilan and 6-MP alternate second. Attention was given to those who survived for more than 10 years, of whom 11 (34%) did not receive any treatment for more than 5 years and even 11 years. 70